The genomic puzzle of Rosai-Dorfman disease

Rosai-Dorfman disease (RDD) was long regarded as a reactive histiocytic proliferation, consistent with its frequent spontaneous regression and the absence of identified clonal drivers. This view began to shift in 2016–2017, when recurrent activating mutations in KRAS and MAP2K1 were identified in a subset of cases, prompting partial reclassification of RDD as a clonal neoplasm. This review synthesises the genetic and genomic testing literature in RDD published 2014–2025, drawing on nineteen cohort studies and conference abstracts identified through a structured PubMed search and citation chaining. Reported mutation-positive rates range from 0% to approximately 83% depending on cohort, sequencing method, and anatomic site, with KRAS and MAP2K1 the most frequently implicated genes. Cutaneous disease shows a distinct NRAS -dominant profile, while intraosseous disease trends toward mutation negativity, though each rests upon a few cohorts. Beyond MAPK, recurrent findings in CSF1R and other receptor tyrosine kinases, alongside a scattered catalog of epigenetic and myeloid-malignancy-associated alterations, indicate that the genomic landscape extends beyond one pathway. Population data remain sparse: Saudi and Japanese cohorts diverge from the North American and Chinese literature dominating this field, but neither is large enough to establish a stable population-level profile. Small samples, heterogeneous platforms, inconsistent testing completeness, and few prospective multi-center cohorts limit how confidently mutation rates can be generalised. This review discusses the competing reactive and neoplastic interpretations of RDD, the concepts needed to interpret its genomic data, and emerging diagnostic and genotype-informed therapeutic developments. RDD is best understood as a genomically defined clonal subset within a broader, poorly characterised population, not a disease fully reclassified from reactive to neoplastic. Prospective, uniformly sequenced, multi-institutional studies including underrepresented populations are needed to resolve this picture.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-11-16
DOI
https://doi.org/10.3389/fonc.2026.2016300
Primary Topic
Histiocytic Disorders and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The genomic puzzle of Rosai-Dorfman disease

Sarah Binhassan
3 links
Frontiers in Oncology
Histiocytic Disorders and Treatments
article

The genomic puzzle of Rosai-Dorfman disease

Sarah Binhassan
article en

Abstract

Rosai-Dorfman disease (RDD) was long regarded as a reactive histiocytic proliferation, consistent with its frequent spontaneous regression and the absence of identified clonal drivers. This view began to shift in 2016–2017, when recurrent activating mutations in KRAS and MAP2K1 were identified in a subset of cases, prompting partial reclassification of RDD as a clonal neoplasm. This review synthesises the genetic and genomic testing literature in RDD published 2014–2025, drawing on nineteen cohort studies and conference abstracts identified through a structured PubMed search and citation chaining. Reported mutation-positive rates range from 0% to approximately 83% depending on cohort, sequencing method, and anatomic site, with KRAS and MAP2K1 the most frequently implicated genes. Cutaneous disease shows a distinct NRAS -dominant profile, while intraosseous disease trends toward mutation negativity, though each rests upon a few cohorts. Beyond MAPK, recurrent findings in CSF1R and other receptor tyrosine kinases, alongside a scattered catalog of epigenetic and myeloid-malignancy-associated alterations, indicate that the genomic landscape extends beyond one pathway. Population data remain sparse: Saudi and Japanese cohorts diverge from the North American and Chinese literature dominating this field, but neither is large enough to establish a stable population-level profile. Small samples, heterogeneous platforms, inconsistent testing completeness, and few prospective multi-center cohorts limit how confidently mutation rates can be generalised. This review discusses the competing reactive and neoplastic interpretations of RDD, the concepts needed to interpret its genomic data, and emerging diagnostic and genotype-informed therapeutic developments. RDD is best understood as a genomically defined clonal subset within a broader, poorly characterised population, not a disease fully reclassified from reactive to neoplastic. Prospective, uniformly sequenced, multi-institutional studies including underrepresented populations are needed to resolve this picture.

Frontiers in OncologyVol. 16
King Saud University (SA)
Good health and well-being
Histiocytic Disorders and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon